DYN
Dyne Therapeutics, Inc.
A clinical-stage biotechnology company developing medicines for inherited muscle diseases such as Duchenne muscular dystrophy and myotonic dystrophy. Its FORCE platform delivers RNA-based therapies directly to muscle tissue. Founded in 2017 and incubated by venture firm Atlas Venture, the company takes its name from the "dyne," a unit of force in physics — a fitting nod to its mission of restoring muscle strength.
CUSIP: 26818M108EnergyUS1 holder
Total Value
$8.82M
Total Shares
397.2K
Net Share Change
-276.7K
Activity
1 selling
Investor
Value
Shares
Weight
Change
